Successful treatment of MRSA native valve endocarditis with oral linezolid therapy: a case report

N Nathani; P Iles; T S J Elliott

doi:10.1016/j.jinf.2005.02.016

Successful treatment of MRSA native valve endocarditis with oral linezolid therapy: a case report

J Infect. 2005 Nov;51(4):e213-5. doi: 10.1016/j.jinf.2005.02.016.

Authors

N Nathani¹, P Iles, T S J Elliott

Affiliation

¹ Critical Care Unit, Department of Critical Care, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK. [email protected]

PMID: 16291272
DOI: 10.1016/j.jinf.2005.02.016

Abstract

Staphylococcal endocarditis is potentially fatal and is now the most common cause of infective endocarditis with a mortality rate of 25-47% [Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users: prognostic features in 102 episodes. Ann Intern Med 1992;117:560-6]. Its treatment requires maintenance of bactericidal level of antibiotics for prolonged periods to attain a culture-negative state. Although intravenous vancomycin is currently the drug of choice for methicillin resistant Staphylococcus aureus (MRSA) endocarditis, we present a case treated successfully with oral linezolid for 4 weeks due to a lack of venous access.

Publication types

Case Reports

MeSH terms

Acetamides / administration & dosage*
Administration, Oral
Adult
Anti-Infective Agents / administration & dosage*
Asthma / complications
Echocardiography / methods
Endocarditis, Bacterial / diagnostic imaging
Endocarditis, Bacterial / drug therapy*
Endocarditis, Bacterial / microbiology
Female
Humans
Linezolid
Methicillin Resistance*
Oxazolidinones / administration & dosage*
Staphylococcal Infections / complications
Staphylococcal Infections / drug therapy*
Staphylococcal Infections / microbiology
Staphylococcus aureus / drug effects
Staphylococcus aureus / isolation & purification

Substances

Acetamides
Anti-Infective Agents
Oxazolidinones
Linezolid